PHARMACEUTICALS related term(s) Drugs

Addresses

State of the Union: President Trump, S645–S649 [24FE], H2287–H2295 [24FE]

Amendments

Accelerating Access to Critical Therapies for ALS Act: reauthorize (S. 4472), S4426 [4AU]

Patents: address infringement of patents that claim biological products (S. 1041), S4198 [21JY]

Bills and resolutions

Abortion: reaffirm safety of medication abortion and preempt State restrictions on dispensing medication abortion (see H.R. 8734), H3346 [11MY]

Accelerating Access to Critical Therapies for ALS Act: reauthorize (see S. 4472), S2171 [30AP] (see H.R. 8205), H2824 [6AP]

Armed Forces: furnish stellate ganglion block to members with post-traumatic stress disorder (see H.R. 8764), H3392 [12MY]

Bureau of Prisons: provide medication assisted treatment for opioid addiction to pregnant women in custody (see H.R. 9756), H4623 [16JY]

CDC: advance population research for chronic pain (see S. 5041), S4187 [21JY]

Centers for Medicare & Medicaid Services: require Center for Medicare and Medicaid Innovation to test model implementing most-favored-nation drug pricing (see H.R. 7837), H2470 [5MR]

——— work with State Medicaid programs to issue guidance on impact of funding cuts and new requirements under One Big Beautiful Bill Act on State agencies and enrollees (see H. Res. 1403), H4364 [30JN]

Children and youth: prohibit gender transition procedures on minors and impose civil penalties on persons who perform such procedures on minors (see S. 4426), S2128 [29AP] (see H.R. 8573), H3294 [29AP]

Colleges and universities: provide for marijuana agricultural research program at 1890 Land-Grant Educational Institutions (see H.R. 9344), H4124 [18JN]

——— streamline process for institutions to research marijuana (see H.R. 8394), H2995 [20AP]

Controlled Substances Act: amend evaluation of substances reviewed for scheduling to more closely align with modern medical knowledge, terminology, and practices (see H.R. 9186), H3990 [8JN]

Courts: establish Federal tort for harm to women caused by chemical abortion drugs (see S. 4066), S1009 [11MR] (see H.R. 7902), H2481 [12MR]

Crime: provide for death penalty for anyone who knowingly deals fentanyl to person who dies from use (see H.R. 8766), H3392 [12MY]

Dept. of Defense: improve access to certain medications under TRICARE program (see S. 4106), S1090 [17MR]

Dept. of Education: prohibit award of Federal education funds to educational institutions and agencies that do not allow for religious exemptions to vaccination requirements (see S. 5128), S4266 [23JY]

Dept. of HHS: adjust which engineered cyclic peptides are qualifying single source drugs relative to drug price negotiation program (see H.R. 8857), H3550 [15MY]

——— ensure that Federally-qualified health centers are not required to pay more than 340B ceiling price for covered outpatient drugs at time of purchase (see H.R. 7391), H2040 [5FE]

——— ensure that women seeking chemical abortion are made aware of risks involved (see H.R. 7237), H1912 [23JA]

——— establish demonstration program to award grants to States to improve provision of recommended immunizations for children, adolescents, and adults through use of mobile vaccination units (see H.R. 7465), H2118 [10FE]

——— establish fair prices for prescription drugs (see H.R. 9040), H3735 [26MY]

——— establish program to develop innovative antimicrobial drugs targeting most challenging pathogens and most threatening infections (see H.R. 7352), H2029 [4FE]

——— establish program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals (see S. 4512), S2278 [13MY]

——— improve access to pre-exposure prophylaxis (PrEP) to reduce transmission of HIV (see S. 3990), S802 [4MR] (see H.R. 7853), H2471 [5MR]

——— issue guidance on strategies under Medicaid and Children’s Health Insurance Program to increase mental health and substance use disorder care provider education, training, recruitment, and retention (see H.R. 9867), H5175 [22JY]

——— issue guidelines for addressing nitazene overdoses (see H.R. 8192), H2821 [2AP]

——— make determinations of exclusivity periods for which licensed biological products are eligible (see S. 4332), S1821 [16AP]

——— make updates to National Vaccine Injury Compensation Program (see H.R. 9672), H4466 [14JY]

——— modernize clinical trials and remove barriers for participation in clinical trials (see S. 4440), S2128 [29AP]

——— promote price transparency in health care sector (see H.R. 9393), H4205 [23JN]

——— provide for appropriate cost-sharing for insulin products covered under private health plans (see S. 4512), S2278 [13MY]

——— provide funding for trained school personnel to administer drugs and devices for emergency treatment of known or suspected opioid overdose (see S. 3588), S89 [7JA] (see H.R. 9251), H4085 [10JN]

——— release of documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers (see S. 4355), S1857 [21AP] (see H.R. 9699), H4543 [15JY]

——— require community health centers to provide behavioral and mental health and substance use disorder services (see H.R. 8201), H2824 [6AP]

Dept. of Labor: impose penalties on third party administrators who withhold certain data from health plan fiduciaries and ensure that data is subject to existing privacy and antidiscrimination laws (see H.R. 9486), H4262 [25JN]

——— issue guidance and regulations regarding opioid overdose reversal medication and employee training (see S. 3812), S552 [10FE] (see H.R. 7479), H2118 [10FE]

——— provide States and local areas information on best practices to address effects of substance use disorder on workforce and provide grants for training related to treatment and prevention (see S. 5263), S4475 [5AU] (see H.R. 8203), H2824 [6AP]

Dept. of Veterans Affairs: award grants to develop, implement, and evaluate approaches and methodologies for prospective randomized control trials for neurorehabilitation treatments for chronic mild traumatic brain injury (see H.R. 6993), H615 [9JA]

——— carry out pilot program to expand access to virtual-based opioid treatment for covered veterans (see H.R. 10037), H5213 [3AU]

——— eliminate copayments for medicines relative to preventive health services (see S. 4217), S1668 [26MR]

——— establish Office of Novel Therapeutics within Veterans Health Administration (see S. 4220), S1668 [26MR]

——— expand access to Veterans Community Care Program to include certain veterans seeking mental health or substance-use services (see H.R. 8737), H3391 [12MY]

——— furnish stellate ganglion block to veterans with post-traumatic stress disorder (see H.R. 8763), H3392 [12MY]

——— improve schedule for rating disabilities (see H.R. 8066), H2675 [24MR]

——— make opioid overdose rescue medications available to veterans and their caregivers (see S. 3758), S442 [2FE]

——— modify Precision Medicine for Veterans Initiative (see H.R. 8115), H2776 [26MR]

——— transmit veteran’s history of opioid prescriptions to Community Care health care provider (see H.R. 8679), H3340 [7MY]

Depts. of Defense and Veterans Affairs: set maximum cost-sharing amount for prescription drugs for Armed Forces members and veterans and set maximum price for prescription drugs procured by Federal agencies (see H.R. 8667), H3340 [7MY]

Depts. of HHS and State: formulate strategy to secure support from foreign countries, multilateral organizations, and others to facilitate development and commercialization of qualified pandemic or epidemic products (see H.R. 7879), H2476 [9MR]

Diseases and disorders: protect against seasonal and pandemic influenza (see H.R. 8447), H3067 [22AP]

Drugs: expand access to methadone through alternative care models using pharmacies (see S. 4941), S3202 [24JN] (see H.R. 9790), H4681 [20JY]

——— mitigate effects of coronavirus pandemic on incentives for development of orphan drugs (see H.R. 7693), H2327 [25FE]

——— modify requirements relating to prescription of controlled substances via Internet (see H.R. 6994), H615 [9JA]

——— prevent importation of illicit pill press machines with intent to counterfeit substances (see S. 4446), S2170 [30AP] (see H.R. 7184), H1171 [21JA]

——— prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (see H.R. 8005), H2620 [19MR]

——— reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (see S. 4189), S1614 [25MR]

——— require out-of-pocket expenditures for drugs to count towards individual’s deductible and out-of-pocket maximum (see H.R. 8270), H2885 [14AP]

——— require that opioid overdose rescue kits be located at public institutions of higher education (see H.R. 8499), H3122 [27AP]

FDA: accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing reciprocal approval mechanism with trusted international regulatory authorities (see H.R. 7953), H2550 [17MR]

——— allow digital communication of prescribing information for drugs, including biological products (see S. 5242), S4432 [4AU]

——— authorize use of investigational individualized medical treatments by patients diagnosed with life-threatening disease or condition or severely debilitating illness (see S. 4698), S2664 [8JN] (see H.R. 9190), H3990 [8JN]

——— clarify process for denying certain petitions whose primary purpose is to delay approval of application submitted relative to certain drugs (see H.R. 8908), H3627 [19MY]

——— codify that default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy (see H.R. 9661), H4466 [14JY]

——— enhance ability of outsourcing facilities to mitigate drug shortages by allowing short-term period to continue supplying market after drug is in shortage (see H.R. 7528), H2217 [12FE]

——— enhance drug manufacturing amount information reporting (see H.R. 8339), H2959 [16AP]

——— establish new prohibited acts relative to dietary supplements (see S. 3797), S509 [5FE] (see H.R. 7407), H2041 [5FE]

——— expand certain authorities relative to recall of controlled substances to apply to all drugs (see H.R. 7980), H2596 [18MR]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (see S. 3697), S290 [27JA]

——— prevent importation of counterfeit, unapproved, misbranded, or adulterated drugs from China or other foreign countries and establish enhanced safeguards for imported drug products (see S. 5043), S4187 [21JY]

——— provide for expedited approval of priority nonprescription drugs (see H.R. 9774), H4680 [20JY]

——— require drug labeling to include original manufacturer and supply chain information (see S. 3788), S509 [5FE] (see H.R. 8269), H2885 [14AP]

——— require regulatory review of pharmaceutical products from Chinese entities (see S. 4327), S1821 [16AP]

——— respect scientific judgment that mifepristone is safe and effective and ensure access to lifesaving, time-sensitive medication abortion care in U.S. is equitable and based on science (see S. Res. 732), S2305 [14MY] (see H. Res. 1285), H3531 [14MY]

——— set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions (see S. 3716), S344 [28JA]

——— streamline review of biosimilar biological products (see S. 5059), S4188 [21JY]

——— strengthen regulation of compounding pharmacies and outsourcing facilities (see S. 3794), S509 [5FE]

——— waive manufacturer payment of user fees during Federal shutdown to provide for continued review of human drug and device submissions during appropriations lapse (see H.R. 9635), H4379 [9JY]

——— withdraw approval of mifepristone for termination of intrauterine pregnancy (see S. 4066), S1009 [11MR] (see H.R. 7902), H2481 [12MR]

FTC: submit report on foreign investment in U.S. pharmaceutical industry (see S. 4987), S4106 [15JY]

GAO: conduct study and submit report on price-related compensation and payment structures in prescription drug supply chain (see S. 3751), S377 [29JA]

——— evaluate and report on in-patient and outpatient drug treatment capacity, availability, and needs of U.S. relative to opioid-use disorders (see H.R. 9676), H4466 [14JY]

Government: prohibit monitoring and regulation of water systems for purposes of surveilling, tracking, or detecting use of, stigmatizing, and further restricting access to medication abortion care (see H. Res. 1389), H4246 [24JN]

Health: address high costs of health care services, prescription drugs, and health insurance coverage in U.S. (see H.R. 8840), H3531 [14MY]

——— end liability shield for vaccine manufacturers (see S. 3853), S578 [11FE]

——— provide private right of action for children and parents of children whose healthy body parts have been damaged by medical professionals practicing or participating in certain interventions (see H.R. 7651), H2258 [23FE]

Health care professionals: protect religious freedom of pharmacists choosing not to dispense or sell abortion-inducing drugs (see H.R. 8366), H2994 [20AP]

Health Resources and Services Administration: provide greater stability, clarity, and transparency in 340B drug discount program (see S. 5244), S4474 [5AU]

——— strengthen 340B drug discount program (see H.R. 9599), H4374 [6JY]

Income: prohibit kickbacks to pharmacy benefit managers (see H.R. 7895), H2481 [12MR]

Insurance: ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care (see S. 4027), S915 [9MR]

——— establish public health plan (see H.R. 9702), H4544 [15JY]

——— preserve patient access to health care providers and prescription drug coverage under Medicare and individual market plans (see S. 4924), S3201 [24JN]

——— prohibit pharmacy benefit managers, insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers (see S. 3822), S552 [10FE]

——— prohibit pharmacy benefit managers and pharmacies from being under common ownership (see S. 4509), S2277 [13MY] (see H.R. 8779), H3452 [13MY]

——— require health insurance coverage of drugs indicated for treatment of autoimmune diseases and certain blood disorders (see H.R. 9192), H3990 [8JN]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by health care provider (see S. 5004), S4107 [15JY]

Medicaid: codify value-based purchasing arrangements and reforms relative to price reporting under such arrangements (see H.R. 7871), H2476 [9MR]

——— ensure adequate access to vaccines under Vaccines for Children program (see H.R. 8425), H3045 [21AP]

——— require coverage for annual lung cancer screening with no cost sharing for certain individuals and expand coverage of counseling and pharmacotherapy for cessation of tobacco use (see S. 4566), S2372 [19MY]

Medicare: establish coverage for certain residential substance use disorder services (see H.R. 9538), H4363 [30JN]

——— provide coverage for pre-exposure prophylaxis (PrEP) furnished by pharmacists (see H.R. 7189), H1171 [21JA]

——— provide review process for adverse national coverage determinations relative to drug coverage of certain new, innovative treatments (see H.R. 9418), H4244 [24JN]

——— require Medicare Payment Advisory Commission reports to Congress on arrangements with pharmacy benefit managers relative to prescription drug plans and Medicare Advantage prescription drug plans (see S. 3729), S377 [29JA]

——— require prescription drug plan sponsors of part D prescription drug plan that use formulary to include certain generic drugs and biosimilar biological products on such formulary (see H.R. 8143), H2789 [27MR]

——— require sponsors of prescription drug plans and Medicare Advantage organizations offering such plans under part D to include certain drugs and biosimilar biological products on formulary (see S. 4323), S1820 [16AP]

Mental health: accelerate development of, and access to, psychedelic drugs that could save lives and reverse crisis of serious mental illness in U.S. (see H.R. 9559), H4364 [30JN]

National Fentanyl Awareness Day: designate (see S. Res. 704), S2129 [29AP] (see H. Res. 1234), H3295 [29AP]

National Naloxone Awareness Day: designate (see S. Res. 770), S2784 [15JN]

National security: alter definitions of ‘‘prohibited technology’’ and ‘‘notifiable technology’’ to include biotechnology (see S. 5316), S4515 [6AU]

NIH: establish National Institute for Biomedical Research and Development (see H.R. 7854), H2471 [5MR]

——— require National Institute of Allergy and Infectious Diseases to award competitive grant for Antibiotic Resistance Leadership Group to facilitate clinical research network on antibiotic resistance (see S. 5237), S4432 [4AU]

Patient Protection and Affordable Care Act: ensure taxpayer funds for health insurance coverage are available only to U.S. citizens, nationals, or aliens lawfully present (see H.R. 7817), H2470 [5MR]

Public Health Service Act: prohibit treatment of biologic as biological product based solely on presence of protein that is clinically inactive component in such biologic (see H.R. 8630), H3330 [30AP]

Social Security: affirm importance to people of U.S. and express that it must be preserved, protected, and strengthened for current and future generations (see S. Res. 579), S115 [8JA]

States: increase compliance with Prescription Drug Monitoring Program (PDMP) requirements by veterinarians (see H.R. 8983), H3723 [21MY]

Substance Abuse and Mental Health Services Administration: award grants to States to expand access to clinically appropriate services for opioid abuse, dependence, or addiction (see H.R. 9675), H4466 [14JY]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: provide funding for programs and activities (see S. 4895), S3200 [24JN] (see H.R. 9759), H4623 [16JY]

Tardive Dyskinesia Awareness Week: designate (see H. Res. 1265), H3342 [7MY]

Taxation: exclude from gross income certain compensation to clinical trial participants (see S. 5127), S4266 [23JY]

——— provide for credits against tax for domestic manufacturing of critical medical supplies and drugs (see S. 4994), S4107 [15JY]

Women: allow greater access to safe and effective oral contraceptive drugs intended for routine use and direct GAO to conduct study on Federal funding of contraceptive methods (see H.R. 8083), H2710 [25MR]

Messages

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the U.S.: President Trump, S1838 [20AP], H2978 [20AP]

Remarks in House

Abortion: prohibit chemical abortions, H1342 [22JA], H4230 [24JN]

——— prohibit chemical abortions performed without presence of health care provider (H.R. 729), H4232 [24JN]

Accelerating Access to Critical Therapies for ALS Act: reauthorize (H.R. 8205), H4652–H4654 [20JY]

CDC: disapprove revised immunization guidelines for children, H669 [13JA]

Cordele, GA: anniversary of Adams Drugstore (business), H3524 [14MY], E415 [4MY]

Dept. of Defense: prohibit TRICARE coverage of gender-related medical treatment, H5003–H5005 [21JY]

——— strike pilot program on modernization of drug testing using voice-based risk assessment technology to identify servicemembers for drug testing, H4970 [21JY]

Dept. of Veterans Affairs: interim rule relative to determining disability benefit eligibility, H2238 [23FE]

——— reimburse State homes for cost of, or furnish to State homes, certain costly medications provided to veterans who receive nursing home care in such State homes (H.R. 1970), H3298 [30AP]

——— stellate ganglion block treatment for post-traumatic stress disorder funding, H3537, H3538 [15MY]

Domestic policy: lower cost of consumer products and increase affordability, H2548 [17MR]

Drugs: require warning label advising that effects of mifepristone can be counteracted and establish hotline to provide information to women seeking to counteract effects of mifepristone (H.R. 796), H4231 [24JN]

FDA: prohibit funding for Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, or Center for Devices and Radiological Health to issue or finalize guidance recommending or requiring testing in dogs, H3863 [4JN]

——— publish final rule relative to nonclinical testing methods (H.R. 2821), H4639, H4640 [20JY]

——— publish final rule relative to nonclinical testing methods (S. 355), H941 [20JA]

Health: address high costs of health care services, prescription drugs, and health insurance coverage in U.S., H3554 [19MY]

Health care professionals: tribute to pharmacists, H1989 [4FE]

Insurance: improve services provided by pharmacy benefit managers, H2237 [23FE]

Kennedy, Sec. of HHS: call for resignation, H911 [15JA]

Medicare: assure pharmacy access and choice for beneficiaries (H.R. 4317), H928 [20JA]

Mental health: accelerate development of, and access to, psychedelic drugs that could save lives and reverse crisis of serious mental illness in U.S., H5055 [22JY]

——— address overprescribing of antidepressants, H3719 [21MY]

Merced, CA: anniversary of Valley Prescription and Compounding Pharmacy, E446 [14MY]

Myers, Wayne: Pennsylvania Pharmacists Association Pharmacist of the Year award recipient, H2487 [16MR]

NIH: establish National Institute for Biomedical Research and Development (H.R. 7854), H2556 [18MR]

St. Marys, GA: anniversary of Camden Pharmacy, H4309 [29JN]

Trump, President: evaluation of administration relative to women’s health, H3448 [13MY]

Remarks in Senate

Accelerating Access to Critical Therapies for ALS Act: reauthorize (S. 4472), S4425 [4AU], S4501 [6AU]

——— reauthorize (S. 4472), unanimous-consent agreement, S4426 [4AU]

Bardstown, KY: tribute to Crume Drug Store, S4430 [4AU]

Budget: create point of order against reconciliation legislation that does not lower out-of-pocket health care costs, S1906 [22AP]

——— establish deficit-neutral reserve fund relative to reducing price of prescription drugs through adoption of Most Favored Nation drug pricing, S1915, S1916 [22AP]

——— establish deficit-neutral reserve fund to study economic impact of confidential drug pricing agreements between Federal agencies and pharmaceutical manufacturers, S1917 [22AP]

Children and youth: prohibit gender transition procedures on minors and impose civil penalties on persons who perform such procedures on minors (S. 4426), S2294 [14MY]

Dept. of Justice: establish task force to conduct investigations and make public findings and records relating to drug pricing agreements with pharmaceutical companies, S2562 [4JN]

Domestic policy: science and research funding, S246 [15JA]

Drugs: lower prescription drug costs for consumers, S2868 [17JN]

——— reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (S. 4189), S2092 [29AP]

FDA: improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (S. 3697), S292 [27JA], S3186 [24JN]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (S. 3697), unanimous-consent request, S3186 [24JN]

——— restore in-person dispensing requirements for chemical abortion drugs, S284 [27JA]

Health: address health care affordability by establishing health savings accounts for out-of-pocket costs, increasing price transparency, and expanding access to safe and nutritious food, S1849 [21AP]

——— address high costs of health care services, prescription drugs, and health insurance coverage in U.S., S2679–S2681 [9JN]

——— support role of U.S. in helping save lives of children and protecting health of people in low-income countries with vaccines and immunization through Gavi, the Vaccine Alliance (organization), S4208 [22JY]

Insurance: improve services provided by pharmacy benefit managers, S1701 [13AP]

——— require group health plans to provide exceptions process for any medication step therapy protocol (S. 2903), S2674 [9JN]

Medicare: assure pharmacy access and choice for beneficiaries, S1701 [13AP]

——— assure pharmacy access and choice for beneficiaries (H.R. 4317), S3923 [14JY]

——— implementation of drug price negotiation program, S65 [7JA]

National Fentanyl Awareness Day: designate (S. Res. 704), S2089, S2109 [29AP]

National Naloxone Awareness Day: designate (S. Res. 770), S2792 [15JN]

Patents: address infringement of patents that claim biological products (S. 1041), S4198, S4199 [21JY]

Senate: legislative priorities, S560 [11FE]

Social Security: affirm importance to people of U.S. and express that it must be preserved, protected, and strengthened for current and future generations (S. Res. 579), S119 [8JA]

Reports filed

Accelerating Access to Critical Therapies for ALS Act Reauthorization: Committee on Energy and Commerce (House) (H.R. 8205) (H. Rept. 119–733), H4378 [9JY]

——— Committee on Health, Education, Labor, and Pensions (Senate) (S. 4472), S4137 [16JY]

Biosimilar Red Tape Elimination Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1954), S4282 [27JY]

Combating Illicit Xylazine Act: Committee on the Judiciary (Senate) (S. 545), S1820 [16AP]

Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 3788), S4283 [27JY]

Expedited Access to Biosimilars Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1414), S4282 [27JY]

FDA Modernization Act 3.0: Committee on Energy and Commerce (House) (H.R. 2821) (H. Rept. 119–706), H4124 [18JN]

Medication Affordability and Patent Integrity Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2658), S4297 [28JY]

PBM Kickback Prohibition Act: Committee on Education and Workforce (House) (H.R. 7895) (H. Rept. 119–729), H4368 [2JY]

Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 3794), S4283 [27JY]

Texts of

H.R. 2821, FDA Modernization Act 3.0, H4639 [20JY]

H.R. 8205, Accelerating Access to Critical Therapies for ALS Act reauthorization, H4653 [20JY]

S. 1041, Affordable Prescriptions for Patients Act, S4199 [21JY]

S. 3797, Prohibiting Tianeptine and Other Dangerous Products Act, S512 [5FE]

S. 4472, Accelerating Access to Critical Therapies for ALS Act reauthorization, S4426 [4AU]

S. 4566, Increasing Access to Lung Cancer Screening Act, S2378 [19MY]

S. Res. 579, affirm importance of Social Security to people of U.S. and express that it must be preserved, protected, and strengthened for current and future generations, S118 [8JA]

S. Res. 704, National Fentanyl Awareness Day, S2135 [29AP]

S. Res. 732, respect FDA scientific judgment that mifepristone is safe and effective and ensure access to lifesaving, time-sensitive medication abortion care in U.S. is equitable and based on science, S2309 [14MY]

S. Res. 770, National Naloxone Awareness Day, S2791 [15JN]